<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03826901</url>
  </required_header>
  <id_info>
    <org_study_id>LP0133-1181</org_study_id>
    <nct_id>NCT03826901</nct_id>
  </id_info>
  <brief_title>Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children</brief_title>
  <official_title>A Phase 1 Open-label, Multi-centre, Single-arm Trial to Evaluate the Safety and Pharmacokinetics (Including MUsT) of Twice Daily Topical Application of Delgocitinib Cream for 8 Weeks in Adults, Adolescents, and Children With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical
      delgocitinib cream applied to pediatric subjects(2-17 years) and adult subjects (18 years and
      above) with atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Anticipated">December 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Week 0 to Week 8</time_frame>
    <description>Number of AEs and number of subjects with AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter - Cmax</measure>
    <time_frame>at Day 8</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter - AUC</measure>
    <time_frame>at Day 8</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter - tmax</measure>
    <time_frame>at Day 8</time_frame>
    <description>tmax</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Part 1: adults and adolescents (12 years and above)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delgocitinib cream (dosage: A mg/g).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: children (2-11 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delgocitinib cream (dosage: B mg/g).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>delgocitinib</intervention_name>
    <description>Cream for topical application</description>
    <arm_group_label>Part 1: adults and adolescents (12 years and above)</arm_group_label>
    <arm_group_label>Part 2: children (2-11 years)</arm_group_label>
    <other_name>LEO 124249</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion criteria (Part 1: adults and adolescents; 12 years and above)

          -  Diagnosis of atopic dermatitis (AD) as defined by the Hanifin and Rajka (1980)
             criteria for AD

          -  Age 12 years and above at baseline

          -  AD involvement of 25-50% treatable body surface area (BSA) at screening and at
             baseline

          -  Moderate to severe AD (Validated Investigator Global Assessment scale for Atopic
             Dermatitis [vIGA-AD] score of at least 3) at screening and at baseline

        Key Inclusion criteria (Part 2: children; 2-11 years)

          -  Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD

          -  Age 2-11 years at baseline

          -  History of AD for at least 3 months (children aged 2-5 years), and at least 12 months
             (children aged 6-11 years)

          -  AD involvement of 30-50% treatable BSA at screening and at baseline

          -  Moderate to severe AD (vIGA-AD score of at least 3) at screening and at baseline

        Key Exclusion criteria (Part 1 and 2: subjects aged 2 years and above)

          -  Active dermatologic conditions that may interfere with the diagnosis of AD

          -  Use of tanning beds or phototherapy within 4 weeks prior to baseline

          -  Systemic treatment with immunosuppressive/modulating drugs or corticosteroids within 4
             weeks prior to baseline or 3 or more bleach baths any week within 4 weeks prior to
             baseline

          -  Treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs),
             topical phosphodiesterase-4, or oral antibiotics within 1 week prior to baseline

          -  Clinically significant infection (systemic infection or serious skin infection
             requiring parenteral treatment) within 4 weeks prior to baseline

          -  Any disorder, which is not stable, and in the investigator's opinion could affect the
             safety of the subject, influence the results of the trial or impede the subject's
             ability to complete the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LEO Pharma investigational site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma investigational site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma investigational site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma investigational site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma investigational site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma investigational site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma investigational site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma investigational site</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma investigational site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma investigational site</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <zip>46-37535</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma investigational site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 1G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma investigational site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma investigational site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adults, pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified IPD can be made available to researchers in a closed environment for a specified period of time.
Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data is available to request after approval of the studied indication.</ipd_time_frame>
    <ipd_url>http://leopharmatrials.com/for-professionals</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

